These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8968960)

  • 1. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
    Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
    J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular immune recognition of botulinum neurotoxin B. The light chain regions that bind human blocking antibodies from toxin-treated cervical dystonia patients. Antigenic structure of the entire BoNT/B molecule.
    Atassi MZ; Jankovic J; Steward LE; Aoki KR; Dolimbek BZ
    Immunobiology; 2012 Jan; 217(1):17-27. PubMed ID: 21962573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping of the antibody-binding regions on the HN-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ
    Protein J; 2004 Jan; 23(1):39-52. PubMed ID: 15115181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody and T cell recognition of the light chain of botulinum neurotoxin A in two high-responder mouse strains.
    Atassi MZ; Oshima M; Dolimbek BZ; Aoki KR
    Immunobiology; 2012 Jan; 217(1):1-7. PubMed ID: 22015045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune recognition of botulinum neurotoxin B: antibody-binding regions on the heavy chain of the toxin.
    Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
    Mol Immunol; 2008 Feb; 45(4):910-24. PubMed ID: 17897717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
    Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
    Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid.
    Rosenberg JS; Middlebrook JL; Atassi MZ
    Immunol Invest; 1997 Jun; 26(4):491-504. PubMed ID: 9246568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855-1296) of the toxin.
    Oshima M; Hayakari M; Middlebrook JL; Atassi MZ
    Mol Immunol; 1997 Oct; 34(14):1031-40. PubMed ID: 9488054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Submolecular recognition profiles in two mouse strains of non-protective and protective antibodies against botulinum neurotoxin A.
    Atassi MZ; Dolimbek GS; Deitiker PR; Aoki KR; Dolimbek BZ
    Mol Immunol; 2005 Aug; 42(12):1509-20. PubMed ID: 15950744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY; Lu JS; Mao YY; Liu FJ; Wang R; Du P; Yu S; Yu YZ; Yang ZX
    Appl Microbiol Biotechnol; 2023 May; 107(10):3205-3216. PubMed ID: 37058230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
    Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
    Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment.
    Atassi MZ; Dolimbek BZ; Jankovic J; Steward LE; Aoki KR
    Mol Immunol; 2008 Sep; 45(15):3878-88. PubMed ID: 18676021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins.
    Atassi MZ; Oshima M
    Crit Rev Immunol; 1999; 19(3):219-60. PubMed ID: 10422600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regions of recognition by blocking antibodies on the light chain of botulinum neurotoxin A: antigenic structure of the entire toxin.
    Dolimbek BZ; Steward LE; Aoki KR; Atassi MZ
    Immunobiology; 2011 Jun; 216(6):698-706. PubMed ID: 21183243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross reaction of tetanus and botulinum neurotoxins A and B and the boosting effect of botulinum neurotoxins A and B on a primary anti-tetanus antibody response.
    Dolimbek BZ; Jankovic J; Atassi MZ
    Immunol Invest; 2002; 31(3-4):247-62. PubMed ID: 12472183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular bases of protective immune responses against botulinum neurotoxin A--how antitoxin antibodies block its action.
    Atassi MZ; Dolimbek BZ; Steward LE; Aoki KR
    Crit Rev Immunol; 2007; 27(4):319-41. PubMed ID: 18197812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
    Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
    J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A peptide-based immunoassay for antibodies against botulinum neurotoxin A.
    Atassi MZ; Dolimbek BZ; Deitiker P; Jankovic J; Aoki KR
    J Mol Recognit; 2007; 20(1):15-21. PubMed ID: 16981247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.
    Yu YZ; Zhang SM; Wang WB; Du Y; Zhu HQ; Wang RL; Zhou XW; Lin JB; Wang S; Yu WY; Huang PT; Sun ZW
    Biochimie; 2010 Oct; 92(10):1315-20. PubMed ID: 20600570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of an Equine Antitoxin by Immunizing the Halla Horse with the Receptor-Binding Domain of Botulinum Neurotoxin Type A1.
    Kim NY; Park KE; Lee YJ; Kim YM; Hong SH; Son WR; Hong S; Lee S; Ahn HB; Yang J; Seo JP; Lim YK; Yu CH; Hur GH; Jeong ST; Lee HS; Song K; Kang TJ; Shin YK; Choi JS; Choi JY
    J Microbiol Biotechnol; 2019 Jul; 29(7):1165-1176. PubMed ID: 31280529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.